Current Clinical Trials

A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)

  • Universal Trial Number: U1111-1259-2920
  • EudraCT Number: 2020-004864-25
  • IND Number: 146391

UT Collaboration and Innovation on Detection, Care, and Treatment of Alzheimer’s Disease and Related Dementia, University of Tennessee (Dr. Zhao and Dr. Crane)

New IDEAS Study 

An observational, open-label, longitudinal cohort study designed to address the the CED provisions of the NCD on beta-amyloid PET. New IDEAS will evaluate the association between amyloid PET and patient-centered outcomes in an expanded and more ethnoracially and clinically diverse group of Medicare participants presenting with cognitive impairment. ClinicalTrials.gov Identifier: NCT04426539

A Phase 3b Multicenter, Randomized Double-blind, placebo controlled Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects with Neuropsychiatric Symptoms Related to Neurogenerative Disease Protocol Number: ACP-103-046 EudraCT Number: 2017-003536-36

52-week open-label extension study of Pimavanserin in Adult and Elderly Subjects with Neuropsychiatric Symptoms Related to Neurodegenerative Disease (ACP-103-4047) EudraCT Number: 2017-004439-36

Physical Activity Together (PAT) trial for older adults with mild cognitive impairment and their romantic partners: A feasibility study

Funds: To support this project, the principal investigator (Dr. Ahn) received (1) start-up funds from the University of Tennessee, Knoxville Office of Research, Innovation & Economic Development and (2) One UT Detection, Care, and Treatment of Alzheimer’s Disease and Related Dementia Seed Funds from the University of Tennessee System. Sub-Investigator (Dr. Crane).

ICARES AD: An Observational Study of Aducanumab in Participants With Alzheimer’s Disease in the US. ClinicalTrials.gov Identifier: NCT05097131